In the earlier version of this article as it was published online on February 10, 2022 (1) and in the printed article, the disclosures of Salvatore Siena and Jeeyun Lee were missing. The HTML and PDF versions of this article were corrected in the online release of the April 1, 2022 issue (2). The publisher regrets the error.
References
1.
Demetri
GD
,
De Braud
F
,
Drilon
A
,
Siena
S
,
Patel
MR
,
Cho
BC
, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors
. Clin Cancer Res
2022
Feb 10 [Epub ahead of print]
.2.
Demetri
GD
,
De Braud
F
,
Drilon
A
,
Siena
S
,
Patel
MR
,
Cho
BC
, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors
. Clin Cancer Res
2022
;28
:1302
–12
.©2022 The Authors; Published by the American Association for Cancer Research
2022
American Association for Cancer Research
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
RSS Feeds